Worse Outcome with Imatinib Mesylate as Neoadjuvant Therapy in Locally Advanced Rectal Gastrointestinal Stromal Tumors: Case Series of Four Patients.
Journal
The Gulf journal of oncology
ISSN: 2078-2101
Titre abrégé: Gulf J Oncolog
Pays: Kuwait
ID NLM: 101500911
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
05
04
2021
entrez:
13
6
2022
pubmed:
14
6
2022
medline:
15
6
2022
Statut:
ppublish
Résumé
Rectal gastrointestinal stromal tumors are rare and optimal treatment is yet to be defined. The aim of this report is to highlight the possible aggressive behavior of four cases of rectal GISTs treated with neoadjuvant imatinib in a tertiary care medical hospital. Four cases of rectal GISTs were retrospectively reviewed for patients demographics, clinical presentation, histology, and imatinib therapy. GISTs were common in men. Age ranged to symptoms were nonspecific. All cases were initially considered to have locally unresectable. Patients received preoperative imatinib. Course was unfavorable. 3 patients died of progressive disease, and one from infectious complications. Rectal GISTs may be aggressive and resistant to medical treatment. Thus only early diagnosis may offer the best chance of recovery. Rectal - gastrointestinal stromal tumor - neoadjuvant imatinib - resistance.
Sections du résumé
BACKGROUND
BACKGROUND
Rectal gastrointestinal stromal tumors are rare and optimal treatment is yet to be defined. The aim of this report is to highlight the possible aggressive behavior of four cases of rectal GISTs treated with neoadjuvant imatinib in a tertiary care medical hospital.
METHODS
METHODS
Four cases of rectal GISTs were retrospectively reviewed for patients demographics, clinical presentation, histology, and imatinib therapy.
RESULTS
RESULTS
GISTs were common in men. Age ranged to symptoms were nonspecific. All cases were initially considered to have locally unresectable. Patients received preoperative imatinib. Course was unfavorable. 3 patients died of progressive disease, and one from infectious complications.
CONCLUSION
CONCLUSIONS
Rectal GISTs may be aggressive and resistant to medical treatment. Thus only early diagnosis may offer the best chance of recovery.
KEY WORDS
BACKGROUND
Rectal - gastrointestinal stromal tumor - neoadjuvant imatinib - resistance.
Substances chimiques
Antineoplastic Agents
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM